Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation

Area of Science:

• Cardiovascular Research
• Immunology
• Pharmacology

Background:

• Inflammation is a key driver of atherosclerotic plaque progression and rupture.
• Reducing local macrophage accumulation is a therapeutic strategy for atherosclerosis.
• Macrophage proliferation, not just recruitment, significantly contributes to plaque inflammation in advanced stages.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting local macrophage proliferation in advanced atherosclerotic plaques.
• To evaluate the efficacy of nanoparticle-delivered simvastatin in reducing plaque inflammation and remodeling.
• To assess the combined effect of short-term nanoparticle intervention and long-term oral statin treatment.

Main Methods:

• Utilized apolipoprotein E deficient (Apoe) mice with advanced atherosclerotic plaques.
• Employed nanoparticle-based delivery of simvastatin to target and inhibit macrophage proliferation within plaques.
• Combined nanoparticle intervention with an eight-week oral statin treatment regimen.

Main Results:

• Nanoparticle-delivered simvastatin rapidly reduced plaque inflammation and induced favorable plaque phenotype remodeling.
• The combined treatment regimen effectively reduced and continuously suppressed plaque inflammation.
• Pharmacological inhibition of local macrophage proliferation demonstrated significant therapeutic benefits.

Conclusions:

• Locally inhibiting macrophage proliferation is an effective strategy for treating inflammation in atherosclerosis.
• Targeted delivery of simvastatin offers a promising therapeutic avenue for managing atherosclerotic plaque progression.
• Combined short-term and long-term statin-based interventions can durably suppress plaque inflammation.